Drugs / REFLOCIBART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04419467 | Sep 2020 → Oct 2022 | diabetic kidney disease | CSL Behring | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REFLOCIBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314868 ↗ |
| Known as | CSL346 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04419467 ↗ |
| Action | Inhibit | “The vascular endothelial growth factor B inhibitor CSL346 (8 or 16 mg/kg q4w) did not reduce urinary albumin-creatinine ratio at week 16 versus placebo in patients with type 2...” PMID 39150859 ↗ Aug 2024 |
| Modality | Monoclonal antibody | “CSL346 is a novel humanized monoclonal antibody that binds VEGF-B with high affinity.” PMID 39150859 ↗ Aug 2024 |
| Route | Intravenous | “Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions” NCT04419467 ↗ |
| Route | Subcutaneous | “Administered as a single intravenous (IV) loading dose followed by subcutaneous (SC) infusions” NCT04419467 ↗ |
| Target | VEGFB | “CSL346 is a novel humanized monoclonal antibody that binds VEGF-B with high affinity.” PMID 39150859 ↗ Aug 2024 |